Since no previous randomized comparison has been carried out between ultra-high and conventional dosage streptokinase therapy of fresh venous thromboses, the NBVL trial was carried out as a prospective, randomized, multicentre, phlebographically monitored comparison of the results and adverse effects of these two fibrinolytic treatment options.
Introduction
To date, all previous comparisons of the results of conventionally dosed thrombolytic streptokinase (SK) therapy and those with ultra-high dosage streptokinase (UHS K) therapy have been retrospective. The aim of the NBVL trial was to study the therapeutic and adverse effects of these two therapies using prospective randomized patient allocation with phlebographic monitoring at defined treatment times.
Patients and methods
The inclusion criteria for the trial were patients who had phlebographic evidence of popliteal, femoral or iliac thromboses and a maximum presumed thrombus age of 14 days, who were aged between 18 and 65 years (older in exceptional cases) and who had consented to treatment.
The exclusion criteria were patients with contraindications to fibrinolytic therapy, with previous thrombosis in the affected leg and previous streptokinase therapy within the past year or a fresh pulmonary embolus requiring treatment.
Randomization was in blocks of six for each of the 11 participating working groups.
Dosage and duration of therapy
The patients in group A were initially given 250 000 U streptokinase within 30 minutes, and then 1.5 million U/h for 6 h (a total of 9 million U per day iv). This dosage was repeated up to two times (omitting the initial dose) after an interval of 18 h.
Patients in group B received the same initial dose and were then given 100 000 U streptokinase/h intravenously for 5 days by continuous infusion. Heparin was given in both groups if the PTT showed inadequate anticoagulation. After three cycles in group A or 5 days in group B, the individual investigators determined subsequent treatment.
Phlebographic monitoring
Phlebographic monitoring was carried out in group A after 72 Ϯ 6 h and in group B after 5 Ϯ 1 days if the vein had not already been shown to be patent earlier by Duplex ultrasound, confirmed by phlebography. Evaluation was according to the IFP-C score (Table 1 ) by a radiologist not involved in treatment.
Laboratory investigations
Before treatment was started, platelet count, fibrinogen, PTT, reptilase time, haemoglobin and urine sediment were determined. During treatment, fibrinogen, PTT and reptilase time were measured at 8-h intervals.
Adverse effects
Allergic reactions, increases in body temperature to more than 38.5°C, haemorrhages with/without stopping therapy or the requirement for transfusion were recorded with information concerning the site. Pulmonary emboli were also recorded.
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Results
The basic data of the 156 patients treated and 133 patients monitored by phlebography were homogeneously distributed between the treatment groups ( Table 2) . Phlebographic monitoring could not be carried out at the time planned in 23 of the 156 patients treated. In 15 cases (9.6% of the total patient group), this was due to early withdrawal of therapy because of adverse effects (Table 3 ) and in eight because the monitoring time-point was missed.
Phlebographic monitoring (Table 4 ) showed an improvement in the IFP score of 47.25% in group A and of only 30.05% in group B (p = 0.007).
Complete patency of a whole venous segment ( Figure 1 ) was more frequent with both dosages in the pelvis than in the thigh or knee region ( Figure 1 ).
In order to make the results more comparable with those in the literature, the cases were analysed according to the number of thrombotic segments ( Table 5 ). This showed that in group A eight of 27 three-segment occlusions and in group B only one of 26 three segment occlusions resolved completely.
With regard to individual segments (Table 6 ), complete patency of completely occluded venous segments occurred more frequently in group A (132 out of 281) than in group B (81 out of 279; p Ͻ 0.01). In contrast, partial patency was only slightly more frequent in group A than in group B. Deterioration with complete or incomplete occlusion of previously patent segments or complete occlusion of previously incompletely occluded segments was detected 11 times in both groups. Baseline phlebography showed that patients aged more than 60 years had more extensive thromboses than younger patients, with mean IFP scores of 5.1 and 5.5 in groups A and B respectively (Table 7) ; the reduction in score of 3.2 with ultra-high dosage therapy was significantly greater (p = 0.003) than with conventional dosage (score difference of 1.1).
The score reduced significantly more in men (1.9) than in women (p = 0.02). Ultra-high dosage therapy led to a greater reduction in score in men than in women (2.6 versus 1.2; p = 0.002). There was no difference in response between right-sided and left-sided thromboses. Lysis of presumed older thromboses was not worse than that of more recent thromboses ( Table 7) .
Adverse effects
No deaths occurred, and the reasons for withdrawal of therapy are shown in Table 3 .
Haemorrhage, particularly in the urogenital tract, occurred significantly less frequently in group A than in group B (Table 8) , and 26.5% of men and 35.2% of women were affected by haemorrhagic complications. Ultra-high dosage caused less haemorrhage in men (9 out of 51) than conventional dosage (18 out of 51); this difference was less marked in women (8 out of 26 versus 11 out of 28). With increasing age, the overall rate of haemorrhage increased with the conventional dosage, but not with ultra-high dosage (Table 9 ).
In group A, the number of haemorrhagic complications was higher (8 out of 27) amongst those with a baseline fibrinogen of more than 446 mg/dl than amongst those with lower baseline fibrinogen (9 out of 50); in group B there was no difference (10 out of 29 versus 19 out of 50). There was a trend towards greater frequency of haemorrhage if the fibrinogen level fell on the first day of treatment to less than 25% of the baseline value, compared with patients Vascular Medicine 1998; 3: 87-94 with smaller falls (group A: 14 out of 56 versus 3 out of 20; group B: 25 out of 62 versus 4 out of 16). The frequency of haemorrhage increased with increasing duration of treat- Difference in score 2.15 1.26 p = 0.007 ment or increased streptokinase dosage administered (Table 10) .
Small pulmonary emboli, which did not require a change in therapy, occurred once in group A and twice in group B. 
Discussion
The efficacy and adverse effects of two different dosages of thrombolytic therapy for fresh leg-pelvis venous thromboses were compared using randomized patient allocation. These treatments have previously been compared only in different patient groups. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The choice of times for comparison of the methods was based on previous experience, which has shown that ultra-high dosage streptokinase therapy works more rapidly than conventional dosage. Exploring all therapeutic options of both dosage procedures would have made comparisons, especially since it was a multicentre trial, very difficult or even impossible from a statisti- Table 5 Results of treatment in relation to extent of venous occlusion.
No. of segments

Three Two One
Patency complete 8 1 8 1 7 5 partial 10 13 10 7 0 2 none 9 12 10 21 3 1 cal point of view (weighing the expected risk of fibrinolytic therapy against the increasing risk with increasing duration of therapy cannot be determined in advance and would have been carried out differently by the individual investigators). Basic discussion concerning the indications for thrombolytic therapy of venous thromboses [13] [14] [15] can be dispensed with, since this trial compared two thrombolytic therapy procedures for identical indications. The inclusion and exclusion criteria for both groups were the usual ones for fibrinolytic therapy of venous thromboses. Regarding the basic data, the only difference was in the site of thrombosis: it cannot be explained why group B had more left-sided thromboses.
The intended duration of treatment was achieved in 83% in the UHSK group (mean 2.5 Ϯ 0.8 cycles) and in only 68% of the conventionally dosed streptokinase group (mean 3.4 Ϯ 1.5 days). It can be concluded that UHSK is more practicable than conventional streptokinase dosing. The number of therapy withdrawals did not differ between the two groups. The monitoring parameter chosen was the IFP-C score. 16, 17 Detailed evaluation of each venous segment, which is like planimetry of the phlebogram with inclusion of 'neighbouring pathways', allows more exact comparison of efficiency than the MARDER score, especially with thrombolytic therapy, since the latter only considers thrombi in the main veins. The disadvantage of the IFP-C score is that the 'neighbouring pathways' are not always Vascular Medicine 1998; 3: 87-94 visualized. The IFP-C score is not suitable for the evaluation of the haemodynamic effects of venous thrombosis.
With regard to the target criterion of phlebographic findings, the mean total score, ultra-high dosage is significantly more effective than conventional dosage (score difference 2.15:1.26 = 1.7). The clearest result is the difference in complete patency of three-segment occlusion ( Table 5 ). If the one-, two-and three-segment occlusions are combined, the UHSK gives a rate of complete patency of 23 out of 65 (35%) compared with 17 out of 63 with conventional streptokinase (27%). Partial patency occurred in 20 out of 65 with UHSK (31%) and 22 out of 63 with conventional dosage streptokinase (35%). Absence of patency occurred in 22 out of 65 (34%) with UHSK and in 24 out of 63 (38%) with conventional therapy. If the cases with complete and incomplete patency are combined, the success rate is 18 out of 27 in group A (67%) and 14 out of 26 in group B (54%) for three-segment occlusions; 18 out of 28 (64%) and 18 out of 29 (62%) respectively for two-segment occlusions; and 7 out of 10 (70%) and 7 out of 8 (87.5%) respectively for one-segment occlusions. Thus a trend can be recognized that UHSK has practically the same effect, regardless of the extent of occlusion, while conventional dosage streptokinase has a poorer effect with more extensive occlusion. It is possible that an improved effect would occur with continued conventional dosage therapy, but this would be associated with a higher rate of adverse effects. If the results are considered with regard to the extent of thrombosis ignoring dosage, three-segment occlusion was followed by complete patency in 9 out of 53 (17%) and partial patency in 23 out of 53 (43%), giving a total of 32 out of 53 (60%). The results for two-segment occlusion were complete patency in 19 out of 57 (33%) and incomplete in 17 out of 57 (30%), giving a total of 36 out of 57 (63%). One-segment occlusion showed the best treatment results: complete patency in 12 out of 18 (67%) and incomplete in 2 out of 18 (11%), giving a total of 14 out of 18 (77%). This confirms the fact that the success of thrombolytic therapy depends upon the extent of venous thrombosis. In relation to the individual venous segments, UHSK had a greater effect than conventional dosage therapy: complete and partial patency in 150 out of 281 (53%) versus 96 out of 279 (34) of segments, with no change in 131 out of 281 (47%) versus 183 out of 279 (66%) of occluded segments.
It cannot be completely explained why male patients who received thrombolysis showed better regression in total score in group A (2.6) and in group B (1.3) than the female patients (1.2 and 1.1, respectively). Since right-sided and left-sided thromboses did not show any differences in lysis, Vascular Medicine 1998; 3: 87-94 the fact that female patients in the group had more leftsided thromboses is not an explanation.
It is also difficult to explain why patients aged more than 60 years old had better resolution of their thromboses with ultra-high dosage streptokinase than younger patients. The most likely reason is that older patients have slower organization of thrombi from the venous wall and thus the thrombi lyse more easily; with conventional streptokinase dosage, the duration of therapy was not long enough to make this difference obvious.
Strangely, presumed older thrombi in this group were no more difficult to lyse than presumed younger thrombi. On comparison with data in the literature, it must be considered that the NBVL trial was not aimed at exploring therapeutic options; with continuation of the therapy, better results might possibly have been achieved with fresher thrombi in both groups.
There are two possible explanations for the lower number of haemorrhagic complications with UHSK treatment than with conventional dosage. First, ultra-high dosage favours activator lysis, with fewer fibrin(ogen) split products and thus less pronounced antithrombin effects; secondly, UHSK treatment can be given for a shorter time and so increased fibrinolytic activity is present for less time than with conventional dosage treatment (this is also shown by the increasing number of haemorrhagic complications with increasing duration of therapy).
In considering the costs of therapy, the higher price of ultra-high dosage must be set against the hospitalization costs. The latter are reduced with ultra-high dosage as a result of the shorter duration of treatment. If the same effect is expected as with conventional dosage as may occur with one-segment occlusions, cost arguments favour conventional dosage. Alternatively, other costs that cannot be calculated exactly arise from the haemorrhagic complications and their treatment. Since these occur less frequently with ultra-high dosage, this dosage seems advantageous on cost grounds. Overall, it can be concluded from this trial that fibrinolytic treatment of leg-pelvis venous thromboses with ultra-high dosage streptokinase shows greater efficacy in a shorter time and with fewer haemorrhagic complications than with conventional dosage. The rate of adverse effects is also not negligible with ultra-high dosage streptokinase and therefore the search for better forms of therapy should continue. In this regard, the indications and modalities for local and regional fibrinolytic therapy 18, 19 need further revision.
